Mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis: signals for hope?

In this Regenerative Medicine perspective, find out more about MSC therapy for ALS.

Go to the profile of Regenerative Medicine
May 02, 2018
Upvote 0 Comment

Based on the distinctive traits of mesenchymal stem cells (MSC), it has been postulated that these cells may play a critical role in regenerative medicine. In addition to the participation of MSC in the repair of mesodermal-derived tissues (bone, cartilage), robust data have suggested that MSC may also play a reparative role in conditions involving damage of cells of ectodermal origin. Several preclinical studies have put forward the concept that MSC therapy may represent an option for the treatment of several neurological disorders and injuries, including amyotrophic lateral sclerosis (ALS). In this review, Carolina Allers, Janet A Jones, Gabriel P Lasala and José J Minguell examine the most representative biomedical literature dealing with cellular, molecular and preclinical studies that have strengthened the notion that cellular therapy represents a feasible and robust option for the treatment of ALS. 

"For ALS patients having no illusion of a panacea, the opening of that clinical trial symbolized the awaited right of hope"

Allers C, Jones JA, Lasala GP, Minguell JJ. Mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis: signals for hope? Regen. Med. 9(5), 637–647 (2014)

Go to the profile of Regenerative Medicine

Regenerative Medicine

Journal, Future Science Group

Regenerative Medicine is an award-winning peer-reviewed journal, in print and web formats. The journal provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats. Among other indexing services Regenerative Medicine is listed by MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus® with an Impact Factor of 2.786 (2014). Each issue contains expertly drafted Reviews, Original Research articles, Perspectives, Editorials, topical insight from international leaders in their field, and additional added-value content. The Senior Editor of the journal is Professor Chris Mason, University College London. You can find out more about Regenerative Medicine at our website (, where you can find the aims and scope of the journal and details of our international editorial board.

No comments yet.